ES2055611T3 - Pdgf resistente a proteasas y metodos de uso. - Google Patents

Pdgf resistente a proteasas y metodos de uso.

Info

Publication number
ES2055611T3
ES2055611T3 ES91913764T ES91913764T ES2055611T3 ES 2055611 T3 ES2055611 T3 ES 2055611T3 ES 91913764 T ES91913764 T ES 91913764T ES 91913764 T ES91913764 T ES 91913764T ES 2055611 T3 ES2055611 T3 ES 2055611T3
Authority
ES
Spain
Prior art keywords
pdgf
polypeptides
methods
proteins
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91913764T
Other languages
English (en)
Inventor
Mark J Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ES2055611T3 publication Critical patent/ES2055611T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE PRESENTAN POLIPEPTIDOS DE CADENA B DE PDGF QUE SE CARACTERIZAN PORLA SUSTITUCION O ELIMINACION DE UN RESIDUO DE LISINA O DE ARGININA EN LA POSICION 27, 28, 32, 79, 80 U 81 DE LA CADENA B NATIVA. TAMBIEN SE PRESENTAN PROTEINAS TIPO PDGF QUE CONTIENEN LOS POLIPEPTIDOS DE CADENA B. LOS POLIPEPTIDOS Y PROTEINAS SE PUEDEN PRODUCIR MEDIANTE EL USO DE CELULAS CULTIVADAS TRANSFECTADAS O TRANSFORMADAS PARA EXPRESAR MOLECULAS DE ADN QUE CODIFICAN LOS POLIPEPTIDOS. LAS PROTEINAS TIPO PDGF SON UTILES COMO COMPONENTES DE MEDIOS DE CULTIVO DE CELULAS Y PARA ACELERAR LA CICATRIZACION DE HERIDAS.
ES91913764T 1990-07-23 1991-07-22 Pdgf resistente a proteasas y metodos de uso. Expired - Lifetime ES2055611T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55721990A 1990-07-23 1990-07-23

Publications (1)

Publication Number Publication Date
ES2055611T3 true ES2055611T3 (es) 1994-08-16

Family

ID=24224518

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91913764T Expired - Lifetime ES2055611T3 (es) 1990-07-23 1991-07-22 Pdgf resistente a proteasas y metodos de uso.

Country Status (10)

Country Link
US (2) US5895755A (es)
EP (1) EP0547064B1 (es)
JP (1) JP2823690B2 (es)
AT (1) ATE107665T1 (es)
AU (1) AU8294991A (es)
CA (1) CA2087969C (es)
DE (1) DE69102651T2 (es)
DK (1) DK0547064T3 (es)
ES (1) ES2055611T3 (es)
WO (1) WO1992001716A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105007A1 (en) * 1995-06-07 2003-06-05 Andre Beaulieu PDGF-betabeta and fibronectin combined in a solid wound dressing for the treatment of wounds
PT1486565E (pt) * 1995-10-11 2008-02-28 Novartis Vaccines & Diagnostic Combinação de pdgf, kgf, igf e igfbp para cicatrização de ferimentos
EP0948538B1 (en) * 1996-12-13 2008-06-11 Novartis Vaccines and Diagnostics, Inc. Analysis and separation of platelet-derived growth factor proteins
DK1659179T3 (da) * 1998-02-05 2011-10-10 Glaxosmithkline Biolog Sa Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
US7608258B2 (en) * 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
JP2006517586A (ja) * 2003-02-04 2006-07-27 ラドウィグ インスティテュート フォー キャンサー リサーチ 幹細胞のｖｅｇｆ−ｂ及びｐｄｇｆ調節
WO2005065269A2 (en) * 2003-12-29 2005-07-21 Am Biosolutions Compositions and method for decreasing the appearance of skin wrinkles
WO2005065419A2 (en) * 2003-12-29 2005-07-21 Am Biosolutions Method of culturing cells
US7678780B2 (en) * 2003-12-29 2010-03-16 Allan Mishra Method of treating cancer using platelet releasate
US7462268B2 (en) * 2004-08-20 2008-12-09 Allan Mishra Particle/cell separation device and compositions
FR2891149B1 (fr) * 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
US20100112081A1 (en) 2008-10-07 2010-05-06 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
CN105085652B (zh) * 2014-05-16 2021-06-22 中国人民解放军军事医学科学院生物工程研究所 血小板衍生生长因子b突变体、其制备方法及用途
CA2962954A1 (en) 2014-10-14 2016-04-21 Samuel Lynch Compositions for treating wounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4801542A (en) * 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5045633A (en) * 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
EP0259632B1 (en) * 1986-08-13 1995-12-13 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
JPH01502669A (ja) * 1987-03-13 1989-09-14 アムジエン・インコーポレーテツド 精製された血小板由来の成長因子及びその精製方法
DE3834079A1 (de) * 1988-10-06 1990-04-12 Biotechnolog Forschung Gmbh Wachstumstimulierendes pdgf-bb und dessen verwendung sowie ein verfahren zu seiner herstellung und der des monomeren
GB9101645D0 (en) * 1991-01-25 1991-03-06 British Bio Technology Compounds

Also Published As

Publication number Publication date
ATE107665T1 (de) 1994-07-15
US5895755A (en) 1999-04-20
CA2087969A1 (en) 1992-01-24
DE69102651D1 (de) 1994-07-28
JP2823690B2 (ja) 1998-11-11
DK0547064T3 (da) 1995-03-20
WO1992001716A1 (en) 1992-02-06
CA2087969C (en) 2001-10-16
AU8294991A (en) 1992-02-18
EP0547064A1 (en) 1993-06-23
DE69102651T2 (de) 1994-10-06
JPH05508775A (ja) 1993-12-09
EP0547064B1 (en) 1994-06-22
US5905142A (en) 1999-05-18

Similar Documents

Publication Publication Date Title
ES2055611T3 (es) Pdgf resistente a proteasas y metodos de uso.
ES2090297T3 (es) Produccion de proteinas que utilizan recombinacion homologa.
FI852547L (fi) Framstaellning av faktor viii och daertill hoerande produkter.
ATE198754T1 (de) Antikörper gegen saugetier-interleukin-4 und peptide verwendbar als antigenen für deren herstellung
DK1115840T3 (da) Afstamningsspecifikke celler og progenitorceller
NO973848D0 (no) Fremgangsmåte til fremstilling av hemoglobinliknende protein
DE69532532D1 (de) Chimerische papillomavirus-ahnliche partikel
DE3786592T3 (de) Transformation von Trichoderma.
HK166495A (en) HIV-1 envelope muteins lacking hypervariable domains
GR80840B (en) Novel polypeptide with a - amylase inhibiting effect, method for the preparation thereof, use and pharmaceutical preparations thereof
DE69130981D1 (de) Expression von makrophagen-induzierbaren proteinen (mips) in hefezellen
ES8402346A1 (es) Procedimiento para la obtencion de lineas de celulas animales y humanas cultivables permanentemente.
EP0336779A3 (en) Polypeptides stabilized by covalent hydrogen bond replacements
ES2065915T3 (es) Procedimiento para aumentar la expresion de polipeptidos en un cultivo de celula recombinante.
ES2047946T3 (es) Metodos de cultivos celulares para producir proteina c activada.
GR3006212T3 (es)
JPS6434371A (en) Periosteal bone forming material
WO1994011510A3 (en) Modulators of hematopoietic progenitor cells
AU525042B2 (en) Ovulation enhancing peptides

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 547064

Country of ref document: ES